 Home > Active Ingredient News > Antitumor Therapy > JCO: Lower dose, better efficacy-Tamoxifen benefits more women!

JCO: Lower dose, better efficacy-Tamoxifen benefits more women!

 Last Update: 2021-03-26
 Source: Internet
 Author: User

Tags

soy health risks

abc 1 2

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Breast cancer is the malignant tumor with the highest incidence of women in the world.

Breast Cancer Globally, breast cancer poses a great threat to human health, both in terms of morbidity and mortality.

It is mainly used as an adjuvant therapy for estrogen receptor-positive breast cancer in premenopausal women and some postmenopausal women.

The drug is also used for chemoprevention in women with a higher risk of breast cancer , but it also increases the risk of uterine lesions, including endometrial polyps, endometrial cancer and endometrial hyperplasia, uterine sarcoma and uterine carcinosarcoma.

Prevention but at the same time increases the risk of uterine lesions, including endometrial polyps, endometrial cancer and endometrial hyperplasia, uterine sarcoma and uterine carcinosarcoma.

Changes in mammography density are representative of the response to tamoxifen treatment.

The study is part of the Swedish mammography screening program (KARISMA Phase II trial).

Screening

The study used 20 mg treatment as the standard dose.

The results showed that between October 1, 2016 and September 30, 2019, 1439 participants were recruited, 566 and 873 premenopausal and postmenopausal women, respectively.

After premenopausal women took 2.

Compared with the 20 mg standard dose group, the incidence of severe vascular symptoms (hot flashes, cold sweats, and night sweats) in the 2.

In summary, when premenopausal women take 2.

When premenopausal women took 2.

references:

Mikael Eriksson, et al.

org/doi/full/10.
1200/JCO.
20.
02598#affiliationsContainer" target="_blank" rel="noopener">Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.